We've put some small files called cookies on your device to make our site work.
We'd also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We'll use a cookie to save your choice. You can read more about our cookies before you choose.
Rituximab as a second line agent for the eradication of inhibitors in patients with acquired haemophilia
NHS England will commission rituximab for second line treatment in the eradication of inhibitors for patients with acquired haemophilia in accordance with the criteria outlined in this document.
